FDA warns on unapproved weight-loss drugs; HIMS slips 3.2%

What happened

Hims & Hers shares fell 3.2% on September 1, 2026 after the FDA warned telehealth companies and compounding pharmacies about unapproved weight-loss drugs, including semaglutide, tirzepatide, and retatrutide. The FDA specifically stated that retatrutide and cagrilintide cannot legally be used in compounding and that it has already warned companies marketing unapproved retatrutide directly to consumers. This latest regulatory action adds to the existing overhang from the July 2026 FTC lawsuit and the earlier FDA crackdown that forced Hims to stop offering compounded GLP-1s in March 2026. However, Hims had already pivoted to branded GLP-1 products like Wegovy and Ozempic, and does not currently appear to market retatrutide or cagrilintide, so the direct revenue impact may be limited. Nevertheless, the warning signals continued regulatory scrutiny on the telehealth weight-loss market, which could raise compliance costs, restrict marketing practices, and dampen investor sentiment for the sector.

Implication

The FDA's action reinforces the regulatory headwind that has pressured HIMS shares since the early 2026 compounded drug reset. While Hims now focuses on branded GLP-1s, the broader crackdown on unapproved weight-loss drugs could increase compliance costs, limit marketing channels, and deter telehealth companies from pursuing investigational drugs like retatrutide. The persistent regulatory overhang, combined with the ongoing FTC lawsuit, raises the probability of operational restrictions that could impair customer acquisition and retention. Management may try to downplay the impact, but the stock's negative reaction shows the market is sensitive to any regulatory escalation. Investors should monitor whether Hims or its peers receive direct FDA warning letters, as that would indicate a more material threat to the business model.

Thesis delta

The FDA's warning adds another regulatory overhang but does not alter the core thesis materially because Hims has already transitioned to branded GLP-1s. However, it underscores the ongoing regulatory risk in the weight-loss category and may cap near-term valuation multiples. The investment stance remains WAIT, with a slightly higher probability of regulatory-induced downside.